The Monitoring Program includes substances which are not on the Prohibited List, but that WADA wishes to monitor in order to detect potential patterns of misuse in sport. A spokesperson for Novo Nordisk said in a statement that the pharmaceutical company, which produces and distributes GLP-1s, agreed with WADAs decision to monitor GLP-1 usage: We are supportive of the WADA recommendation, and we strongly discourage use/promotion outside the indicated population and approved label. Advertisement A spokesperson for Eli Lilly, another company that manufactures and distributes GLP-1s, said: Zepbound (tirzepatide) and Foundayo (orforglipron) are indicated for use, along with diet and exercise, for adults with obesity or overweight and a weight-related comorbidity
It names fasting glucose, HbA1c, a lipid panel, and kidney function testing by eGFR as baseline laboratory work a provider may request
Drug Deliv Transl Res 9:62530
The peptides discussed (BPC-157, TB-500, and others) are not FDA-approved for cosmetic, surgical, or any medical use
